ATE208773T1 - Chinoxalindione - Google Patents

Chinoxalindione

Info

Publication number
ATE208773T1
ATE208773T1 AT97908156T AT97908156T ATE208773T1 AT E208773 T1 ATE208773 T1 AT E208773T1 AT 97908156 T AT97908156 T AT 97908156T AT 97908156 T AT97908156 T AT 97908156T AT E208773 T1 ATE208773 T1 AT E208773T1
Authority
AT
Austria
Prior art keywords
quinoxalindione
Prior art date
Application number
AT97908156T
Other languages
English (en)
Inventor
David John Bull
Christopher Lee Carr
Michael Jonathan Fray
Elisabeth Colette Loui Gautier
Charles Eric Mowbray
Alan Stobie
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of ATE208773T1 publication Critical patent/ATE208773T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Luminescent Compositions (AREA)
AT97908156T 1996-03-09 1997-02-27 Chinoxalindione ATE208773T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones

Publications (1)

Publication Number Publication Date
ATE208773T1 true ATE208773T1 (de) 2001-11-15

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97908156T ATE208773T1 (de) 1996-03-09 1997-02-27 Chinoxalindione

Country Status (42)

Country Link
US (1) US6376490B1 (de)
EP (1) EP0885212B1 (de)
JP (1) JP3110467B2 (de)
KR (1) KR100288099B1 (de)
CN (1) CN1103770C (de)
AP (1) AP767A (de)
AR (1) AR006119A1 (de)
AT (1) ATE208773T1 (de)
AU (1) AU717972B2 (de)
BG (1) BG63340B1 (de)
BR (1) BR9707851A (de)
CA (1) CA2248366C (de)
CO (1) CO4770976A1 (de)
CZ (1) CZ292792B6 (de)
DE (1) DE69708269T2 (de)
DK (1) DK0885212T3 (de)
DZ (1) DZ2188A1 (de)
EA (1) EA001730B1 (de)
ES (1) ES2163742T3 (de)
GB (1) GB9605027D0 (de)
HN (1) HN1998000034A (de)
HR (1) HRP970132A2 (de)
HU (1) HUP9900975A3 (de)
ID (1) ID18112A (de)
IL (1) IL125491A (de)
IS (1) IS4811A (de)
MA (1) MA26422A1 (de)
NO (1) NO984058L (de)
NZ (1) NZ331060A (de)
OA (1) OA10850A (de)
PE (2) PE43398A1 (de)
PL (1) PL329032A1 (de)
PT (1) PT885212E (de)
SI (1) SI0885212T1 (de)
SK (1) SK283467B6 (de)
TN (1) TNSN97044A1 (de)
TR (1) TR199801782T2 (de)
TW (1) TW454004B (de)
UY (1) UY24482A1 (de)
WO (1) WO1997032873A1 (de)
YU (2) YU39698A (de)
ZA (1) ZA971987B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP982A (en) 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
JP3873746B2 (ja) * 2000-05-19 2007-01-24 アステラス製薬株式会社 トリアゾール誘導体
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
KR101170995B1 (ko) 2004-02-06 2012-08-08 닛산 가가쿠 고교 가부시키 가이샤 에너지 저장 디바이스용 전극 및 그 제조 방법
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2150248A4 (de) * 2007-01-16 2011-06-29 Univ Johns Hopkins Glutamat-rezeptorantagonisten und anwendungsverfahren
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
CN106928157A (zh) * 2007-05-17 2017-07-07 株式会社半导体能源研究所 三唑衍生物
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(qc, ec 2.3.2.5)의 헤테로사이클릭 억제제
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014121883A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2550456B2 (ja) * 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors

Also Published As

Publication number Publication date
EA199800702A1 (ru) 1999-04-29
SI0885212T1 (en) 2002-02-28
BG63340B1 (bg) 2001-10-31
TNSN97044A1 (fr) 2005-03-15
KR19990087614A (ko) 1999-12-27
DK0885212T3 (da) 2002-03-25
NZ331060A (en) 2000-01-28
IS4811A (is) 1998-07-27
TW454004B (en) 2001-09-11
CA2248366A1 (en) 1997-09-12
UY24482A1 (es) 2000-09-29
IL125491A0 (en) 1999-03-12
HN1998000034A (es) 1999-02-09
CN1103770C (zh) 2003-03-26
TR199801782T2 (xx) 1998-12-21
GB9605027D0 (en) 1996-05-08
CZ292792B6 (cs) 2003-12-17
IL125491A (en) 2003-07-06
CZ286498A3 (cs) 1999-07-14
JP3110467B2 (ja) 2000-11-20
CA2248366C (en) 2002-06-04
BG102760A (en) 1999-09-30
AP767A (en) 1999-09-29
CN1213369A (zh) 1999-04-07
AP9700947A0 (en) 1997-04-30
DE69708269D1 (de) 2001-12-20
SK283467B6 (sk) 2003-08-05
HUP9900975A3 (en) 2001-12-28
DZ2188A1 (fr) 2002-12-02
AU717972B2 (en) 2000-04-06
SK121498A3 (en) 2000-10-09
BR9707851A (pt) 1999-07-27
HUP9900975A2 (hu) 1999-07-28
NO984058D0 (no) 1998-09-03
JPH11506123A (ja) 1999-06-02
MA26422A1 (fr) 2004-12-20
YU39698A (sh) 1999-03-04
ZA971987B (en) 1998-09-07
AU2023197A (en) 1997-09-22
AR006119A1 (es) 1999-08-11
EA001730B1 (ru) 2001-08-27
YU41199A (sh) 2001-09-28
PE43398A1 (es) 1998-08-29
EP0885212B1 (de) 2001-11-14
DE69708269T2 (de) 2002-07-25
KR100288099B1 (ko) 2001-05-02
HRP970132A2 (en) 1998-06-30
CO4770976A1 (es) 1999-04-30
NO984058L (no) 1998-11-06
EP0885212A1 (de) 1998-12-23
OA10850A (en) 2001-08-16
PE58199A1 (es) 1999-06-11
US6376490B1 (en) 2002-04-23
PT885212E (pt) 2002-02-28
ES2163742T3 (es) 2002-02-01
WO1997032873A1 (en) 1997-09-12
PL329032A1 (en) 1999-03-01
ID18112A (id) 1998-03-05

Similar Documents

Publication Publication Date Title
BR9703884A (pt) Cicloalcanopiridinas
BR9704464A (pt) Evisceradora
ATE262512T1 (de) Arylalkanoylpyridazine
ATE208773T1 (de) Chinoxalindione
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
DE59609702D1 (de) Pulversprüheinrichtung
BR9703563A (pt) Hidromancal
BR9707467A (pt) 1-Pirazol-3-iletil-4-indol-3-ilpiperdinas
BR9703835A (pt) Hidromancal
DE59706319D1 (de) Carbamoylcarbonsäureamidoxime
BR9708716A (pt) 3-cianoaril-pirazóis
DE59610630D1 (de) Paradontalsonde
ATE267568T1 (de) Epithese
BR9601152A (pt) Drenovaporvia
BR9604349A (pt) Xapisqueira
BR7603147U (pt) Simborgueup
BR7603380U (pt) Abratporta
BR7603492U (pt) Protemilk
BR9600112A (pt) Conaço
BR9600914A (pt) Lipodecantador
BR9600920A (pt) Otimizador-turbinado-nb
BR9605529A (pt) Banzo
BR9602174A (pt) Lecton massoterapeutico
BR9603463A (pt) Hidro-coleta
BR9603698A (pt) Hidro-escova dorso-lombar

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee